Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

Abstract Adenoviral vectors have been explored as vaccine agents for a range of infectious diseases, and their ability to induce a potent and balanced immune response made them logical candidates to apply to the COVID-19 pandemic. The unique molecular characteristics of these vectors enabled the rap...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Samir Andrade Mendonça, Reka Lorincz, Paul Boucher, David T. Curiel
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2884d62b3ff9428ba246fbb13c87a66c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2884d62b3ff9428ba246fbb13c87a66c
record_format	dspace
spelling	oai:doaj.org-article:2884d62b3ff9428ba246fbb13c87a66c2021-12-02T14:53:40ZAdenoviral vector vaccine platforms in the SARS-CoV-2 pandemic10.1038/s41541-021-00356-x2059-0105https://doaj.org/article/2884d62b3ff9428ba246fbb13c87a66c2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00356-xhttps://doaj.org/toc/2059-0105Abstract Adenoviral vectors have been explored as vaccine agents for a range of infectious diseases, and their ability to induce a potent and balanced immune response made them logical candidates to apply to the COVID-19 pandemic. The unique molecular characteristics of these vectors enabled the rapid development of vaccines with advanced designs capable of overcoming the biological challenges faced by early adenoviral vector systems. These successes and the urgency of the COVID-19 situation have resulted in a flurry of candidate adenoviral vector vaccines for COVID-19 from both academia and industry. These vaccines represent some of the lead candidates currently supported by Operation Warp Speed and other government agencies for rapid translational development. This review details adenoviral vector COVID-19 vaccines currently in human clinical trials and provides an overview of the new technologies employed in their design. As these vaccines have formed a cornerstone of the COVID-19 global vaccination campaign, this review provides a full consideration of the impact and development of this emerging platform.Samir Andrade MendonçaReka LorinczPaul BoucherDavid T. CurielNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Samir Andrade Mendonça Reka Lorincz Paul Boucher David T. Curiel Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
description	Abstract Adenoviral vectors have been explored as vaccine agents for a range of infectious diseases, and their ability to induce a potent and balanced immune response made them logical candidates to apply to the COVID-19 pandemic. The unique molecular characteristics of these vectors enabled the rapid development of vaccines with advanced designs capable of overcoming the biological challenges faced by early adenoviral vector systems. These successes and the urgency of the COVID-19 situation have resulted in a flurry of candidate adenoviral vector vaccines for COVID-19 from both academia and industry. These vaccines represent some of the lead candidates currently supported by Operation Warp Speed and other government agencies for rapid translational development. This review details adenoviral vector COVID-19 vaccines currently in human clinical trials and provides an overview of the new technologies employed in their design. As these vaccines have formed a cornerstone of the COVID-19 global vaccination campaign, this review provides a full consideration of the impact and development of this emerging platform.
format	article
author	Samir Andrade Mendonça Reka Lorincz Paul Boucher David T. Curiel
author_facet	Samir Andrade Mendonça Reka Lorincz Paul Boucher David T. Curiel
author_sort	Samir Andrade Mendonça
title	Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
title_short	Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
title_full	Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
title_fullStr	Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
title_full_unstemmed	Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
title_sort	adenoviral vector vaccine platforms in the sars-cov-2 pandemic
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2884d62b3ff9428ba246fbb13c87a66c
work_keys_str_mv	AT samirandrademendonca adenoviralvectorvaccineplatformsinthesarscov2pandemic AT rekalorincz adenoviralvectorvaccineplatformsinthesarscov2pandemic AT paulboucher adenoviralvectorvaccineplatformsinthesarscov2pandemic AT davidtcuriel adenoviralvectorvaccineplatformsinthesarscov2pandemic
_version_	1718389373190275072

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

Ejemplares similares